NeuroSense PrimeC Achieves Primary Endpoint in Phase 2b ALS Study with Significant TDP-43 Reduction

summarizeSummary

NeuroSense Therapeutics announced its lead ALS drug, PrimeC, met its primary endpoint in a Phase 2b study by significantly reducing TDP-43, a key disease biomarker, reinforcing its potential as a disease-modifying therapy.

check_boxKey Events · Product Development and Regulatory · NRSN

• Primary Endpoint Met in ALS Study

  PrimeC achieved a statistically significant reduction in TDP-43 levels in its Phase 2b PARADIGM study for ALS, a first for a randomized, double-blind, placebo-controlled trial.

• Targeting ALS Pathological Hallmark

  TDP-43 is present in over 97% of ALS cases and is a central driver of disease progression, indicating PrimeC's engagement with a core disease mechanism.

• Consistent Positive Clinical Data

  These findings build on previously reported statistically significant slowing of ALSFRS-R decline and a ~15-month median survival benefit.

• Advancing to Phase 3

  The company has already secured FDA clearance to initiate its global Phase 3 (PARAGON) study, with trial preparations underway.

auto_awesomeAnalysis · NRSN · Life Sciences

This filing reports highly positive Phase 2b clinical trial results for NeuroSense's lead ALS drug candidate, PrimeC. The statistically significant reduction in TDP-43, a defining pathological hallmark of ALS, provides strong biological evidence of the drug's disease-modifying potential. This critical finding, combined with previously reported benefits in slowing disease progression and improving survival, significantly de-risks the drug's development and supports its advancement into a pivotal Phase 3 study, for which FDA clearance has already been secured.